NCT01688999View on ClinicalTrials.gov

Cabozantinib for Advanced Urothelial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

September 11, 2012

Primary Completion Date

December 11, 2017

Study Completion Date

September 14, 2020

Conditions
Urothelial CarcinomaUrethral NeoplasmsUrinary Bladder NeoplasmsKidney Neoplasms
Interventions
DRUG

Cabozantinib

60 mg by mouth (PO) daily each 28 day cycle. Treatment continues until toxicity or disease progression.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01688999 - Cabozantinib for Advanced Urothelial Cancer | Biotech Hunter | Biotech Hunter